Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
AGENT-797 by MiNK Therapeutics for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
AGENT-797 by MiNK Therapeutics for Esophageal Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
AGENT-797 by MiNK Therapeutics for Ocular Melanoma: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Ocular Melanoma. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Duodenal Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Duodenal Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Transitional Cell Cancer (Urothelial Cell Cancer)....
AGENT-797 by MiNK Therapeutics for Thymoma (Thymic Epithelial Tumor): Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Thymoma (Thymic Epithelial Tumor). According to...
AGENT-797 by MiNK Therapeutics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Kidney Cancer (Renal Cell Cancer). According...
AGENT-797 by MiNK Therapeutics for Cervical Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Colorectal Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Rectal Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Rectal Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Gastric Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Pancreatic Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Solid Tumor: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
AGENT-797 by MiNK Therapeutics for Prostate Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...
AGENT-797 by MiNK Therapeutics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to...
AGENT-797 by MiNK Therapeutics for Acute Respiratory Distress Syndrome: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Acute Respiratory Distress Syndrome. According to...
AGENT-797 by MiNK Therapeutics for Testicular Cancer: Likelihood of Approval
AGENT-797 is under clinical development by MiNK Therapeutics and currently in Phase II for Testicular Cancer. According to GlobalData, Phase...